Innovation Alliance on Tuberculosis Diagnosis and Treatmen...
The Successful Opening of the Annual International Meeting...
The 2018 National Symposium of Heads of TB Hospitals in Sh...
The Successful Opening of the 4th International TB Forum a...
The Successful Opening of the Fourth ‘China DR-TB Forum’
The ‘Xiehe MDT Seminar’at Xian
The Successful Opening of the National Academic Conference...
The Successful Opening of the 1st Meeting of the Standing ...
Establishment of a Long-term Platform-The Assembly of the ...
Seminar on the Piloting Phase of the TB Patient Management...
China Tuberculosis Clinical Trial Consortium （CTCTC, hereafter,the consortium）serves as a nation-wide platform for collaboratively carrying out TB-related clinical trials. Its membership is consisted of numerous domestically and internationally renowned TB research teams and other relevant stakeholders who are committed to the clinical research and development of novel anti-TB agents, new preexposure vaccines and diagnostics. Founded in September 2013, the consortium adopts a governing system of the council, and led by the Capital Medical University’s Beijing Chest Hospital who occupies the council’s president-ship. A special office has been set up within the structure of the China Disease Control’s(CDC) TB Clinical and Prevention Center to undertake the daily operations of the consortium. A long-term collaboration has been established between the consortium and the United States National Institute of Health (NIH), who via its subsidiary the Family Health International 360 (FHI 360) has provided for the founding and development of the consortium with an all round technical support. In 2017, the consortium has formerly become one of the subsidiaries of the Innovation Alliance on Tuberculosis Diagnosis and Treatment (Beijing) (hereafter,IATB).
The National Tuberculosis Remote Platform of Professional Consultation and Training was unveiled on 23rd March 2012 in Beijing. Currently its coverage has extended to some 190 medical institutions across 31 provinces and regions in China. Utilizing remote communication technologies,the platform has undertaken a multitude of operations including medical consultation (multi-disciplinary consultation, consultation of complicated cases), medical training programs, professional exchanges and interactions, patient management, emergency assistance to name just a few. Thanks to its versatility, the platform has played a vital role in a number of major domestic emergencies, and grown into the largest remote professional platform in the field nation-wide.